DRI Healthcare

### Overview of DRI HealthcareFounded in 1989, DRI Healthcare is a pioneering private equity firm specializing in global pharmaceutical royalty monetization. It has deployed over $2.5 billion, acquiring more than 70 drug royalties across various therapeutic areas, with a focus on mid-sized transactions primarily in oncology, rare diseases, ophthalmology, and immunology. The firm emphasizes sustainability, diversity, and corporate governance, with a commitment to fostering a diverse and inclusive team.### Goals and PhilosophyDRI Healthcare aims to provide capital to biopharmaceutical innovators while building a diversified portfolio of investments in medicines that positively impact health. The firm emphasizes best practice governance and actively engages with its unitholders to align with stakeholders' interests. Its operational framework is office-based, and it focuses on delivering value through strategic partnerships.### Investment ThesisThe firm's business model is centered on managing and growing a diversified portfolio of pharmaceutical royalties. DRI Healthcare is positioned to capitalize on anticipated growth in the global pharmaceuticals and biotechnology markets, aiming for attractive growth in cash royalty receipts over the long term. The company is publicly held and has been recognized for its active engagement in the industry.